No CrossRef data available.
Article contents
Role of Folic acid as adjuvant treatment in Schizophrenia: A randomized controlled trial
Published online by Cambridge University Press: 19 July 2023
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction
Schizophrenia is a chronic psychiatric illness with symptoms in positive, negative and cognitive domain.The interplay of dietary folic acid intake with common genetic variants that influence folate metabolism, has potential implications for Schizophrenia pathogenesis and treatment.Therefore, it’s deficiency has been identified as a risk factor for Schizophrenia through epidemiologic, biochemical and gene association studies.
Objectives
1-To assess the efficacy of folic acid supplementation on severity of symptoms and overall functional status of patients
2-To assess the correlation of serum folate levels with symptom severity and overall functional status of patients
Methods
A randomized control trial study was carried out in the inpatient department of a psychiatric tertiary care centre on 40 participants (29 males and 11 females)who were between the ages of 18 – 55 years,met diagnostic criteria for Schizophrenia (ICD 10) and had at least 2 years of illness duration while those with a co-morbid psychiatric illness, medical illness and substance abuse were excluded. The participants were then randomly allocated into two groups (experimental Group A which received 5mg folic/day along with anti psychotic drugs and control Group B which received only anti psychotic drugs) and followed up for 3 months. Blood sample for measuring serum folate level was obtained from the experimental group at the beginning and at the end of the study period. Scales applied were Positive and Negative Syndrome Scale(PANSS) for symptom severity and Global Assessment of Functioning scale(GAF) for overall functional status.
Results
Table 2
A significant difference (p value< 0.05) was observed in PANSS scores at the end of the study between experimental group and control group( table 1) and also in GAF scores between both the groups after 3 months(table 2). At the end of the study period,a strong negative correlation(r= -0.9) was found between serum folate level and total PANSS score in the experimental group (figure 1) while the correlation between GAF score and serum folate level was strongly positive (r= 0.8) (figure 2).Table 1
| PANSS (3 Month) | Group A(n=20) | Group B (n=20) | P value |
|---|---|---|---|
| Positive | 16.8±2.80 | 22.9±3.37 | 0.036 |
| Negative | 14.3±3.32 | 15.1±2.61 | 0.18 |
| General | 17.95±2.52 | 21.85±3.18 | 0.0001 |
| Total | 45.95±3.41 | 58±3.49 | 0.00249 |
| GAF | Group A(n=20) | Group B (n=20) | P value |
|---|---|---|---|
| 0 MONTH | 23.25±3.43 | 22.7±2.90 | 0.3 |
| 3 MONTH | 65.75±4.22 | 44.9±7.09 | 0.0256 |
Image:
Image 2:
Conclusions
Our study is among the few to use a randomized controlled study design for assessing the effect of folic acid supplementation on severity of symptoms and global functioning in Schizophrenia,strongly suggesting the use of folic acid as an adjuvant treatment for Schizophrenia.
Disclosure of Interest
None Declared
- Type
- Abstract
- Information
- European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S634 - S635
- Creative Commons
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.- Copyright
- © The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
You have
Access
Open access
Comments
No Comments have been published for this article.